Adant (Syringe) Instructions for Use

Marketing Authorization Holder

Meiji Seika Pharma, Co. Ltd. (Japan)

Dosage Form

Adant

Syringe 2.5 ml: 25 mg

Dosage Form, Packaging, and Composition

One syringe (2.5 ml) of Adant contains 25 mg of sodium hyaluronate.

Therapeutic Category

Synovial fluid replacement

Properties

Medical device.

Hyaluronic acid has physical properties that make it possible to use this substance as a replacement for synovial fluid impaired by the inflammatory process.

Thus, by restoring the physical characteristics of the joint fluid, hyaluronic acid increases mobility and reduces pain in joints affected by osteoarthritis or periarthritis.

Furthermore, the drug induces the synthesis of high molecular weight hyaluronic acid, similar in structure to “normal” hyaluronic acid, in synovial joints affected by chronic degenerative or inflammatory processes.

Without this stimulus, the molecular weight of hyaluronic acid synthesized by synoviocytes is below normal.

This mechanism of action explains the prolonged clinical effect of sodium hyaluronate, which is 10 times greater than the effect calculated from intra-articular clearance and metabolism.

Intra-articular administration of this agent improves joint function, relieves pain caused by osteoarthritis of the knee and shoulder joints.

It improves joint mobility and normalizes the composition of the synovial fluid.

Furthermore, this agent is used for injection into the carpometacarpal joint in patients suffering from rhizarthrosis.

Scope of Application

Osteoarthritis of the knee and shoulder joints; osteoarthritis of the carpometacarpal joint of grades I, II, and III; pain and limited mobility of other synovial joints as a result of degenerative and post-traumatic changes.

ICD codes

Dosage Regimen

Generally, intra-articular administration once a week for 5 consecutive weeks is recommended.

It is injected directly into the cavity of the knee joint, into the shoulder joint (joint cavity, subacromial bursa, or tendon sheath of the long head of the biceps), carpometacarpal joint, or into other affected synovial joints.

For the carpometacarpal joint, two injection methods are recommended depending on the severity of osteoarthritis: the lateral external approach (grade I rhizarthrosis) and the interdigital/into the first web space approach (grade II and III rhizarthrosis).

The choice of a particular method of administration of this agent depends on the individual characteristics of each patient.

Administration of the drug is best performed under endoscopic guidance.

In any case, the dose selection depends on the severity of symptoms.

Side Effects

Local reactions urticaria and itching are possible; in some cases – transient post-injection pain and swelling, as well as redness, burning sensation, and heaviness at the injection site.

General reactions shock reactions are extremely rare.

Contraindications

Hypersensitivity to sodium hyaluronate.

Use During Pregnancy and Breastfeeding

Although preclinical studies have not revealed teratogenic properties, the safety of this agent during pregnancy has not been studied.

Therefore, during pregnancy or suspected pregnancy, this agent should be used with caution.

Sodium hyaluronate is secreted into the milk of animals, so it is recommended to discontinue breastfeeding during the use of this agent.

Special Precautions

Use of this agent may cause an exacerbation of the inflammatory process in patients with osteoarthritis.

In this case, administration is recommended after the inflammatory symptoms have subsided.

To prevent the development of post-injection pain, it is recommended to rest the affected joint.

Use with caution in patients with a history of allergies and in patients with impaired liver function.

Use with caution in elderly patients, as many physiological functions of the body are reduced in the elderly.

Since the safety of this agent in children has not been studied, it should be used with caution.

Drug Interactions

Mixing the drug with quaternary ammonium salts, including benzalkonium chloride, or with chlorhexidine is not allowed due to the development of precipitation.

Storage Conditions

Store at 2°C (36°F) to 30°C (86°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.